Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Other Indications |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 21 - 60 |
| Updated: | 10/20/2018 |
| Start Date: | December 2018 |
| End Date: | December 2022 |
| Contact: | Diana Martinez, MD |
| Email: | dm437@cumc.columbia.edu |
| Phone: | 646-774-6160 |
PLEASE NOTE: This study recruits patients who are being seen at the ENT service of Columbia
University Medical Center.
Tinnitus, or ringing in the ears, is a very common problem that often accompanies hearing
loss. It affects up to 1 in 10 adults, and about 30% of people who experience chronic
tinnitus find it very distressing. In these patients, symptoms of depression and anxiety
often accompany tinnitus and there are no approved treatments. Clinical trials are ongoing to
test a glutamate NMDA receptor antagonist (called esketamine), which is injected into the
inner ear. However, the preliminary results with this medication show that it only works for
tinnitus that results from acute injury. It does not treat tinnitus resulting from
progressive hearing loss.
Research in humans and animals suggest that the neurotransmitters glutamate and GABA are
important in the development and maintenance of tinnitus. This data shows that
over-activation of the NMDA receptor and a decrease in GABA signaling in the brain play a
crucial role. Previous studies show that ketamine, which an antagonist at the NMDA receptor,
increases GABA levels in the brain in participants with depression. Thus, in this experiment,
this study will test the effect of ketamine on tinnitus, since it blocks the NMDA glutamate
receptor and increase GABA levels.
Two groups of participants will be included in this study: those who experience distress
(symptoms of anxiety or depression) with tinnitus and those who have tinnitus but do not
experience distress. Each participant will receive both ketamine and placebo on different
days. Magnetic Resonance Spectroscopy (MRS) scans will be
University Medical Center.
Tinnitus, or ringing in the ears, is a very common problem that often accompanies hearing
loss. It affects up to 1 in 10 adults, and about 30% of people who experience chronic
tinnitus find it very distressing. In these patients, symptoms of depression and anxiety
often accompany tinnitus and there are no approved treatments. Clinical trials are ongoing to
test a glutamate NMDA receptor antagonist (called esketamine), which is injected into the
inner ear. However, the preliminary results with this medication show that it only works for
tinnitus that results from acute injury. It does not treat tinnitus resulting from
progressive hearing loss.
Research in humans and animals suggest that the neurotransmitters glutamate and GABA are
important in the development and maintenance of tinnitus. This data shows that
over-activation of the NMDA receptor and a decrease in GABA signaling in the brain play a
crucial role. Previous studies show that ketamine, which an antagonist at the NMDA receptor,
increases GABA levels in the brain in participants with depression. Thus, in this experiment,
this study will test the effect of ketamine on tinnitus, since it blocks the NMDA glutamate
receptor and increase GABA levels.
Two groups of participants will be included in this study: those who experience distress
(symptoms of anxiety or depression) with tinnitus and those who have tinnitus but do not
experience distress. Each participant will receive both ketamine and placebo on different
days. Magnetic Resonance Spectroscopy (MRS) scans will be
Tinnitus has a prevalence of approximately 1 in 10 adults in the United States. Among those
with tinnitus, 36% had nearly constant symptoms and almost 30% of those report that their
tinnitus as a big or a very big problem. Currently there are few effective treatments for
tinnitus, and no approved medications. Cognitive behavioral and retraining therapy provide
some relief, but many patients fail to respond.
Animal research and human studies indicate that maladaptive plasticity plays a role in
tinnitus, which involves glutamatergic signaling largely at the NMDA and AMPA receptors.
Additionally, GABA signaling has been shown to be impaired in tinnitus. Rodent models show a
diminished sensitivity to GABA signaling and human magnetic resonance spectroscopy (MRS)
studies show decreased GABA levels in the auditory cortex.
Ketamine is a non-competitive NMDA receptor antagonist that has also been shown to activate
AMPA receptors, and modulates ongoing plasticity. Additionally, ketamine activates a
subpopulation of cortical GABAergic interneurons and projection neurons and increases GABA
levels in the human brain, measured with MRS. Ketamine is FDA approved as an anesthetic, and
recent work has demonstrated its efficacy in treating refractory depression and chronic pain.
Importantly, these demonstrate that low dose ketamine, at doses lower than those required for
anesthesia, are effective in lifting depressed mood and improving the sensation of chronic
pain.
For many, tinnitus has an important affective component to it, with distress and co-morbid
symptoms of depression and anxiety. The onset and severity of tinnitus can correlate with
stressful events, and it has been posited that stress lowers the threshold of perception, and
unmasks tinnitus. Tinnitus then triggers more anxiety and depressed mood, which in turn
reinforces the symptoms. An advantage of ketamine may be its effect on depression and
anxiety, in addition to tinnitus, to interrupt this cycle.
The goal of this study is to perform a proof-of-concept preliminary study of ketamine in
tinnitus associated with sensori-neural hearing loss. This will be studied both in
participants who report depressed mood and anxiety and those who do not. MRS imaging will be
used to assess ketamine-induced changes in GABA in the auditory cortex.
with tinnitus, 36% had nearly constant symptoms and almost 30% of those report that their
tinnitus as a big or a very big problem. Currently there are few effective treatments for
tinnitus, and no approved medications. Cognitive behavioral and retraining therapy provide
some relief, but many patients fail to respond.
Animal research and human studies indicate that maladaptive plasticity plays a role in
tinnitus, which involves glutamatergic signaling largely at the NMDA and AMPA receptors.
Additionally, GABA signaling has been shown to be impaired in tinnitus. Rodent models show a
diminished sensitivity to GABA signaling and human magnetic resonance spectroscopy (MRS)
studies show decreased GABA levels in the auditory cortex.
Ketamine is a non-competitive NMDA receptor antagonist that has also been shown to activate
AMPA receptors, and modulates ongoing plasticity. Additionally, ketamine activates a
subpopulation of cortical GABAergic interneurons and projection neurons and increases GABA
levels in the human brain, measured with MRS. Ketamine is FDA approved as an anesthetic, and
recent work has demonstrated its efficacy in treating refractory depression and chronic pain.
Importantly, these demonstrate that low dose ketamine, at doses lower than those required for
anesthesia, are effective in lifting depressed mood and improving the sensation of chronic
pain.
For many, tinnitus has an important affective component to it, with distress and co-morbid
symptoms of depression and anxiety. The onset and severity of tinnitus can correlate with
stressful events, and it has been posited that stress lowers the threshold of perception, and
unmasks tinnitus. Tinnitus then triggers more anxiety and depressed mood, which in turn
reinforces the symptoms. An advantage of ketamine may be its effect on depression and
anxiety, in addition to tinnitus, to interrupt this cycle.
The goal of this study is to perform a proof-of-concept preliminary study of ketamine in
tinnitus associated with sensori-neural hearing loss. This will be studied both in
participants who report depressed mood and anxiety and those who do not. MRS imaging will be
used to assess ketamine-induced changes in GABA in the auditory cortex.
Inclusion Criteria:
- Participant aged 21-60 referred by physician in the ENT service at the Columbia
University Medical Center.
- Tinnitus associated with at least mild sensori-neural hearing loss of at least 6
months duration
- Score at least 32 on the Tinnitus Handicap Inventory and a score of 5dB or greater on
the minimum masking level
- Tinnitus not due to medical disease (other than sensorineural hearing loss)
- Score of at least 14 on the Hamilton Depression Rating Scales with a score of at least
2 on the Hamilton Anxiety Rating Scale (in the distressed group).
Exclusion Criteria:
- DSM-V psychiatric disorders other than mild-moderate depression and anxiety, including
substance use disorder.
- History of recreational ketamine use, recreational PCP use,exposure to ketamine as an
anesthetic, or an adverse reaction to ketamine
- Currently taking psychotropic medication (e.g.antipsychotics, antidepressants,
benzodiazepines)
- Presence or positive history of significant medical or neurological illness, including
high blood pressure (SBP >140, DBP > 90), cardiac illness, abnormality on EKG, head
injury.
- Pregnancy, abortion, or lack of effective birth control during 15 days before the scan
- Metal implants, pacemaker, other metal (e.g. shrapnel or surgical prostheses) or
paramagnetic objects contained within the
- Medicinal patch that cannot be removed for the scans.
We found this trial at
1
site
Click here to add this to my saved trials
